Agno Pharma, a contract development and manufacturing organization based in the United States, has officially completed the acquisition of Lubrizol Particle Sciences Inc. This strategic move encompasses the drug product formulation technology integral to Particle Sciences Inc. and includes the Bethlehem, PA, development and manufacturing site, boasting approximately 65 employees.
Particle Sciences, established in 1991, specializes in pre-clinical and clinical stage drug product formulation, offering a comprehensive range of supporting services such as analytic, bioanalytic, physical characterization, and manufacturing. The company excels in handling poorly soluble and highly potent compounds in both sterile and non-sterile environments.
With the acquisition of Particle Sciences, Agno Pharma gains enhanced capability and capacity, allowing the expansion of its drug product formulation and clinical manufacturing services to a global clientele. Following this acquisition, Agno intends to make additional investments in clinical scale manufacturing services, spanning from sterile liquid manufacturing and filling services to the micronization of sterile powder filling capabilities. This strategic move solidifies Agno's dedication to delivering a comprehensive end-to-end solution for its esteemed customers across the pharmaceutical sector on a global scale.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!